3-gluconamidopropyl methacrylamide | 1127335-27-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-gluconamidopropyl methacrylamide
• 英文别名: GAPMA；(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxy-N-[3-(2-methylprop-2-enoylamino)propyl]hexanamide
• CAS: 1127335-27-6
• 化学式: C₁₃H₂₄N₂O₇
• 分子量: 320.343
• InChiKey: BKLSJAXAPJSSOE-CHWFTXMASA-N

物化性质

• 沸点：
  791.7±60.0 °C(predicted)
• 密度：
  1.340±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -3
• 重原子数：
  22
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  159
• 氢给体数：
  7
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  葡萄糖酸内酯 、 N-(3-氨基丙基)甲基丙烯酸盐 盐酸盐 在 三乙胺 作用下， 以 甲醇 为溶剂， 以65.4%的产率得到3-gluconamidopropyl methacrylamide
  参考文献：
  名称：

  通过可逆多共价苯硼酸/顺式二醇聚合物复合物动态引入细胞粘附因子

  摘要：

  在这项工作中，通过 PBA/顺式二醇聚合物复合物中的可逆多共价相互作用成功地证明了在基质上动态引入生物活性 RGD 肽。这些可逆的、稳定的多重相互作用位点，除了一个长期可及的聚合物接头外，还通过特定的生物分子交换（例如，葡萄糖或果糖）实现了对细胞粘附的“可逆”控制。这种由生物分子触发的非侵入性策略在实时生物研究中显示出巨大的应用前景，并模拟天然生物分子反馈系统，因此在医学诊断和再生医学中具有潜在的应用价值。

  DOI：

  10.1021/ja501664f

文献信息

• Non-viral transfection systems
  申请人：Universität Bayreuth

  公开号：EP2522689A1

  公开（公告）日：2012-11-14

  The present invention relates to the use of polyelectrolyte particles as non-viral vectors. In particular, the present invention relates to the use of a polyelectrolyte particle for transferring in vitro, in vivo or ex vivo an anionic substance into a cell, wherein the polyelectrolyte particle is a star-shaped particle that has a common branching centre and a specific number of polymer chains radiating outward therefrom, or is a spherical micelle comprising a specific number of polymer chains radiating outward from the micelle core. Such polyelectrolyte particles have applications in many fields, particularly in molecular biology, but also in gene therapy and for siRNA applications. The present invention further relates to an in vitro method for transferring an anionic substance into a cell by using such polyelectrolyte particles, a complex containing such polyelectrolyte particles and to their medical and biotechnological use.

  本发明涉及聚电解质颗粒作为非病毒载体的用途。特别是，本发明涉及一种聚电解质微粒，用于在体外、体内或体外将一种阴离子物质转移到细胞中，其中的聚电解质微粒是一种星形微粒，具有一个共同的分支中心和从该中心向外辐射的特定数量的聚合物链，或者是一种球形胶束，包括从胶束核心向外辐射的特定数量的聚合物链。这种聚电解质微粒可应用于许多领域，特别是分子生物学领域，也可应用于基因治疗和 siRNA 领域。本发明还涉及一种利用这种聚电解质微粒将阴离子物质转移到细胞中的体外方法、一种含有这种聚电解质微粒的复合物以及它们在医疗和生物技术方面的用途。
• Utilization of magnetic nanoparticles as intracellular pull-down system
  申请人：Universität Bayreuth

  公开号：EP2523002A1

  公开（公告）日：2012-11-14

  The present invention relates to a method for obtaining intracellular molecules having specific affinity for a polyelectrolyte particle comprising a functionalized magnetic nanoparticle by transferring said polyelectrolyte particle into a eukaryotic cell comprising the intracellular molecule, wherein a conjugate is formed between the polyelectrolyte particle and the intracellular molecule. By recovering the conjugate from the eukaryotic cell and isolating the intracellular molecule from the conjugate, the intracellular molecule can be obtained and subsequently analyzed. The present invention further relates to the use of such a polyelectrolyte particle for identifying and/or isolating a subset of eukaryotic cells comprising the polyelectrolyte particle from a plurality of eukaryotic cells, and for isolating a complex formed between the polyelectrolyte particle and a polyanion from polyelectrolyte particles not in complex with the polyanion. Furthermore, the present invention relates to the use of an intracellular molecule for modifying the expression of a nucleic acid transfected into a eukaryotic cell by means of such a polyelectrolyte particle.

  本发明涉及一种获取对包含功能化磁性纳米粒子的聚电解质颗粒具有特异性亲和力的细胞内分子的方法，其方法是将所述聚电解质颗粒转移到包含细胞内分子的真核细胞中，其中在聚电解质颗粒和细胞内分子之间形成共轭物。通过从真核细胞中回收轭合物并从轭合物中分离出胞内分子，可获得胞内分子并进行后续分析。本发明还涉及使用这种聚电解质颗粒从多个真核细胞中鉴定和/或分离出包含该聚电解质颗粒的真核细胞子集，以及从未与多阴离子形成复合物的聚电解质颗粒中分离出聚电解质颗粒与多阴离子形成的复合物。此外，本发明还涉及一种细胞内分子的用途，该分子用于改变通过这种聚电解质颗粒转染到真核细胞中的核酸的表达。
• WÄSSRIGE BINDEMITTELZUSAMMENSETZUNGEN
  申请人：BASF SE

  公开号：EP2582761A1

  公开（公告）日：2013-04-24
• AQUEOUS BINDER COMPOSITIONS
  申请人：Amthor Stephan

  公开号：US20110312240A1

  公开（公告）日：2011-12-22

  The present invention relates to aqueous binder compositions which are based on aqueous polymer dispersions, to processes for preparing them, and to their uses. The aqueous binder composition comprises: a) a water-insoluble polymer P in the form of dispersed polymer particles, i.e., in the form of an aqueous polymer dispersion, the polymer P being obtainable by polymerization of ethylenically unsaturated monomers M, the monomers M comprising: 90% to 99.9% by weight, more particularly 92% to 99.5% by weight and especially 93% to 99% by weight, based on the total amount of monomers M, of at least one neutral, monoethylenically unsaturated monomer M1 of low water-solubility; and 0.1% to 10% by weight, more particularly 0.5% to 7% by weight and especially 1% to 5% by weight, based on the total amount of monomers M, of at least one monoethylenically unsaturated monomer M2 which is selected from monoethylenically unsaturated monomers which have at least two hydroxyl groups attached to vicinal C atoms, and monomers which carry a functional group which can be converted by hydrolysis into two hydroxyl groups attached to vicinal C atoms; and b) boric acid and/or at least one salt of boric acid.
• [DE] WÄSSRIGE BINDEMITTELZUSAMMENSETZUNGEN<br/>[EN] AQUEOUS BINDING AGENT COMPOSITIONS<br/>[FR] COMPOSITIONS DE LIANTS AQUEUSES
  申请人：BASF SE

  公开号：WO2011157792A1

  公开（公告）日：2011-12-22

  Die vorliegende Erfindung betrifft wässrige Bindemittelzusammensetzungen auf Basis wässriger Polymerdispersionen, Verfahren zu ihrer Herstellung und ihre Verwendungen. Die wässrige Bindemittelzusammensetzung enthält: a) ein wasserunlösliches Polymer P in Form dispergierter Polymerpartikel, d.h. in Form einer wässrigen Polymerdispersion, wobei das Polymer P erhältlich ist durch Polymerisation ethylenisch ungesättigter Monomere M, wobei die Monomere M umfassen: 90 bis 99,9 Gew.-%, insbesondere 92 bis 99,5 Gew.-% und speziell 93 bis 99 Gew.-%, bezogen auf die Gesamtmenge an Monomeren M, wenigstens eines gering wasserlöslichen, neutralen, monoethylenisch ungesättigten Monomers M1; und 0,1 bis 10 Gew.-%, insbesondere 0,5 bis 7 Gew.-% und speziell 1 bis 5 Gew.-%, bezogen auf die Gesamtmenge an Monomeren M, wenigstens eines monoethylenisch ungesättigten Monomers M2, das ausgewählt ist unter monoethylenisch ungesättigten Monomeren, die wenigstens zwei, an vicinale C-Atome gebundene Hydroxylgruppen aufweisen, und Monomeren, die eine funktionale Gruppen tragen, welche durch Hydrolyse in zwei, an vicinale C-Atome gebundene Hydroxylgruppen überführt werden können; und b) Borsäure und/oder wenigstens ein Salz der Borsäure.